{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:36:19Z","timestamp":1794587779546,"version":"4.9.1"},"reference-count":336,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41582-020-0389-4","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T16:02:59Z","timestamp":1597420979000},"page":"529-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":546,"title":["Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2716-2045","authenticated-orcid":false,"given":"Sarah J.","family":"Tabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Flower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-7887","authenticated-orcid":false,"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"389_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 1, 1\u201321 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"389_CR2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-444-63233-3.00009-9","volume":"147","author":"H Paulson","year":"2018","unstructured":"Paulson, H. Repeat expansion diseases. Handb. Clin. Neurol. 147, 105\u2013123 (2018).","journal-title":"Handb. Clin. Neurol."},{"key":"389_CR3","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"SJ Evans","year":"2013","unstructured":"Evans, S. J. et al. Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J. Neurol. Neurosurg. Psychiatry 84, 1156\u20131160 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"389_CR4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153b","author":"DR Langbehn","year":"2010","unstructured":"Langbehn, D. R., Hayden, M. R. & Paulsen, J. S. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153b, 397\u2013408 (2010).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"389_CR5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross, C. A. et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204\u2013216 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"389_CR6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000304","volume":"5","author":"GA Palidwor","year":"2009","unstructured":"Palidwor, G. A. et al. Detection of alpha-rod protein repeats using a neural network and application to huntingtin. PLoS Comput. Biol. 5, e1000304 (2009).","journal-title":"PLoS Comput. Biol."},{"key":"389_CR7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/molbev\/msm258","volume":"25","author":"M Tartari","year":"2008","unstructured":"Tartari, M. et al. Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol. Biol. Evol. 25, 330\u2013338 (2008).","journal-title":"Mol. Biol. Evol."},{"key":"389_CR8","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1074\/jbc.M112.413575","volume":"288","author":"Z Zheng","year":"2013","unstructured":"Zheng, Z., Li, A., Holmes, B. B., Marasa, J. C. & Diamond, M. I. An N-terminal nuclear export signal regulates trafficking and aggregation of huntingtin (Htt) protein exon 1. J. Biol. Chem. 288, 6063\u20136071 (2013).","journal-title":"J. Biol. Chem."},{"key":"389_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0169-328X(95)00124-B","volume":"33","author":"DA Bessert","year":"1995","unstructured":"Bessert, D. A., Gutridge, K. L., Dunbar, J. C. & Carlock, L. R. The identification of a functional nuclear localization signal in the Huntington disease protein. Brain Res. Mol. Brain Res 33, 165\u2013173 (1995).","journal-title":"Brain Res. Mol. Brain Res"},{"key":"389_CR10","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/hmg\/ddg156","volume":"12","author":"J Xia","year":"2003","unstructured":"Xia, J., Lee, D. H., Taylor, J., Vandelft, M. & Truant, R. Huntingtin contains a highly conserved nuclear export signal. Hum. Mol. Genet. 12, 1393\u20131403 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir, J. et al. Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811\u2013823 (1995).","journal-title":"Cell"},{"key":"389_CR12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","volume":"11","author":"S Zeitlin","year":"1995","unstructured":"Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue. Nat. Genet. 11, 155\u2013163 (1995).","journal-title":"Nat. Genet."},{"key":"389_CR13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou, F. & Humbert, S. The biology of huntingtin. Neuron 89, 910\u2013926 (2016).","journal-title":"Neuron"},{"key":"389_CR14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas, H. D. et al. Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 131, 1057\u20131068 (2008).","journal-title":"Brain"},{"key":"389_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/537977","author":"EB Johnson","year":"2019","unstructured":"Johnson, E. B. et al. Dynamics of cortical degeneration over a decade in Huntington\u2019s disease. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/537977 (2019).","journal-title":"bioRxiv"},{"key":"389_CR16","first-page":"553","volume":"85","author":"DM Mann","year":"1993","unstructured":"Mann, D. M., Oliver, R. & Snowden, J. S. The topographic distribution of brain atrophy in Huntington\u2019s disease and progressive supranuclear palsy. Acta Neuropathol. 85, 553\u2013559 (1993).","journal-title":"Acta Neuropathol."},{"key":"389_CR17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00310376","volume":"88","author":"H Heinsen","year":"1994","unstructured":"Heinsen, H. et al. Cortical and striatal neurone number in Huntington\u2019s disease. Acta Neuropathol. 88, 320\u2013333 (1994).","journal-title":"Acta Neuropathol."},{"key":"389_CR18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1471-4159.2010.06672.x","volume":"113","author":"I Han","year":"2010","unstructured":"Han, I., You, Y., Kordower, J. H., Brady, S. T. & Morfini, G. A. Differential vulnerability of neurons in Huntington\u2019s disease: the role of cell type-specific features. J. Neurochem. 113, 1073\u20131091 (2010).","journal-title":"J. Neurochem."},{"key":"389_CR19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","volume":"17","author":"DE Ehrnhoefer","year":"2011","unstructured":"Ehrnhoefer, D. E., Sutton, L. & Hayden, M. R. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17, 475\u2013492 (2011).","journal-title":"Neuroscientist"},{"key":"389_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/srep44849","volume":"7","author":"DJ Hensman Moss","year":"2017","unstructured":"Hensman Moss, D. J. et al. Huntington\u2019s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer\u2019s disease. Sci. Rep. 7, 44849 (2017).","journal-title":"Sci. Rep."},{"key":"389_CR21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","volume":"15","author":"A Hodges","year":"2006","unstructured":"Hodges, A. et al. Regional and cellular gene expression changes in human Huntington\u2019s disease brain. Hum. Mol. Genet. 15, 965\u2013977 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"MA Pouladi","year":"2013","unstructured":"Pouladi, M. A., Morton, A. J. & Hayden, M. R. Choosing an animal model for the study of Huntington\u2019s disease. Nat. Rev. Neurosci. 14, 708\u2013721 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"389_CR23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ilar.48.4.356","volume":"48","author":"S Ramaswamy","year":"2007","unstructured":"Ramaswamy, S., McBride, J. L. & Kordower, J. H. Animal models of Huntington\u2019s disease. ILAR J. 48, 356\u2013373 (2007).","journal-title":"ILAR J."},{"key":"389_CR24","first-page":"149","volume":"22","author":"XJ Li","year":"2015","unstructured":"Li, X. J. & Li, S. Large animal models of Huntington\u2019s disease. Curr. Top. Behav. Neurosci. 22, 149\u2013160 (2015).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"389_CR25","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990\u20131993 (1997).","journal-title":"Science"},{"key":"389_CR26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2005.03348.x","volume":"95","author":"G Hoffner","year":"2005","unstructured":"Hoffner, G., Island, M. L. & Djian, P. Purification of neuronal inclusions of patients with Huntington\u2019s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J. Neurochem. 95, 125\u2013136 (2005).","journal-title":"J. Neurochem."},{"key":"389_CR27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/hmg\/7.5.783","volume":"7","author":"JK Cooper","year":"1998","unstructured":"Cooper, J. K. et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 7, 783\u2013790 (1998).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0896-6273(00)80405-5","volume":"19","author":"CA Ross","year":"1997","unstructured":"Ross, C. A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19, 1147\u20131150 (1997).","journal-title":"Neuron"},{"key":"389_CR29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(97)08360-8","volume":"351","author":"SW Davies","year":"1998","unstructured":"Davies, S. W. et al. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 351, 131\u2013133 (1998).","journal-title":"Lancet"},{"key":"389_CR30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)81782-1","volume":"95","author":"F Saudou","year":"1998","unstructured":"Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55\u201366 (1998).","journal-title":"Cell"},{"key":"389_CR31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","volume":"431","author":"M Arrasate","year":"2004","unstructured":"Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805\u2013810 (2004).","journal-title":"Nature"},{"key":"389_CR32","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.1073\/pnas.0503634102","volume":"102","author":"EJ Slow","year":"2005","unstructured":"Slow, E. J. et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl Acad. Sci. USA 102, 11402\u201311407 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR33","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1016\/j.bpj.2012.04.050","volume":"102","author":"L Pieri","year":"2012","unstructured":"Pieri, L., Madiona, K., Bousset, L. & Melki, R. Fibrillar \u03b1-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J. 102, 2894\u20132905 (2012).","journal-title":"Biophys. J."},{"key":"389_CR34","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1074\/jbc.M111.252577","volume":"287","author":"LG Nucifora","year":"2012","unstructured":"Nucifora, L. G. et al. Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J. Biol. Chem. 287, 16017\u201316028 (2012).","journal-title":"J. Biol. Chem."},{"key":"389_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015245","volume":"5","author":"P Lajoie","year":"2010","unstructured":"Lajoie, P. & Snapp, E. L. Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS ONE 5, e15245 (2010).","journal-title":"PLoS ONE"},{"key":"389_CR36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nsmb1215","volume":"14","author":"Y Nagai","year":"2007","unstructured":"Nagai, Y. et al. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14, 332\u2013340 (2007).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"389_CR37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nchembio.694","volume":"7","author":"J Miller","year":"2011","unstructured":"Miller, J. et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol. 7, 925\u2013934 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"389_CR38","volume":"2","author":"SJ Sahl","year":"2012","unstructured":"Sahl, S. J., Weiss, L. E., Duim, W. C., Frydman, J. & Moerner, W. E. Cellular inclusion bodies of mutant huntingtin exon 1 obscure small fibrillar aggregate species. Sci. Rep. 2, 895 (2012).","journal-title":"Sci. Rep."},{"key":"389_CR39","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3753","volume":"4","author":"J Leitman","year":"2013","unstructured":"Leitman, J., Ulrich Hartl, F. & Lederkremer, G. Z. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nat. Commun. 4, 2753 (2013).","journal-title":"Nat. Commun."},{"key":"389_CR40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/ddm311","volume":"17","author":"T Takahashi","year":"2008","unstructured":"Takahashi, T. et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet. 17, 345\u2013356 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR41","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1074\/jbc.M109.093708","volume":"285","author":"J Legleiter","year":"2010","unstructured":"Legleiter, J. et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J. Biol. Chem. 285, 14777\u201314790 (2010).","journal-title":"J. Biol. Chem."},{"key":"389_CR42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.molcel.2018.07.032","volume":"71","author":"A Ast","year":"2018","unstructured":"Ast, A. et al. mHTT seeding activity: a marker of disease progression and neurotoxicity in models of Huntington\u2019s disease. Mol. Cell 71, 675\u2013688.e6 (2018).","journal-title":"Mol. Cell"},{"key":"389_CR43","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","volume":"110","author":"K Sathasivam","year":"2013","unstructured":"Sathasivam, K. et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl Acad. Sci. USA 110, 2366\u20132370 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/exnr.1998.7005","volume":"156","author":"KA Sieradzan","year":"1999","unstructured":"Sieradzan, K. A. et al. Huntington\u2019s disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol. 156, 92\u201399 (1999).","journal-title":"Exp. Neurol."},{"key":"389_CR45","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","volume":"17","author":"CE Wang","year":"2008","unstructured":"Wang, C. E. et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington\u2019s disease. Hum. Mol. Genet. 17, 2738\u20132751 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nbd.2011.12.032","volume":"46","author":"V Castiglioni","year":"2012","unstructured":"Castiglioni, V., Onorati, M., Rochon, C. & Cattaneo, E. Induced pluripotent stem cell lines from Huntington\u2019s disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway. Neurobiol. Dis. 46, 30\u201340 (2012).","journal-title":"Neurobiol. Dis."},{"key":"389_CR47","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.stem.2012.04.027","volume":"11","author":"HD iPSC Consortium","year":"2012","unstructured":"HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington\u2019s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11, 264\u2013278 (2012).","journal-title":"Cell Stem Cell"},{"key":"389_CR48","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/hmg\/11.23.2905","volume":"11","author":"W Yang","year":"2002","unstructured":"Yang, W., Dunlap, J. R., Andrews, R. B. & Wetzel, R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905\u20132917 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR49","doi-asserted-by":"crossref","DOI":"10.1038\/srep19180","volume":"6","author":"E Monsellier","year":"2016","unstructured":"Monsellier, E., Bousset, L. & Melki, R. \u03b1-Synuclein and huntingtin exon 1 amyloid fibrils bind laterally to the cellular membrane. Sci. Rep. 6, 19180 (2016).","journal-title":"Sci. Rep."},{"key":"389_CR50","first-page":"3678","volume":"126","author":"M Costanzo","year":"2013","unstructured":"Costanzo, M. et al. Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. J. Cell Sci. 126, 3678\u20133685 (2013).","journal-title":"J. Cell Sci."},{"key":"389_CR51","doi-asserted-by":"crossref","first-page":"RRN1210","DOI":"10.1371\/currents.RRN1210","volume":"3","author":"F Herrera","year":"2011","unstructured":"Herrera, F., Tenreiro, S., Miller-Fleming, L. & Outeiro, T. F. Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr. 3, RRN1210 (2011).","journal-title":"PLoS Curr."},{"key":"389_CR52","doi-asserted-by":"crossref","first-page":"E5427","DOI":"10.1073\/pnas.1516217112","volume":"112","author":"DT Babcock","year":"2015","unstructured":"Babcock, D. T. & Ganetzky, B. Transcellular spreading of huntingtin aggregates in the Drosophila brain. Proc. Natl Acad. Sci. USA 112, E5427\u2013E5433 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR53","volume":"6","author":"MMP Pearce","year":"2015","unstructured":"Pearce, M. M. P., Spartz, E. J., Hong, W., Luo, L. & Kopito, R. R. Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain. Nat. Commun. 6, 6768 (2015).","journal-title":"Nat. Commun."},{"key":"389_CR54","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/nn.3761","volume":"17","author":"E Pecho-Vrieseling","year":"2014","unstructured":"Pecho-Vrieseling, E. et al. Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat. Neurosci. 17, 1064\u20131072 (2014).","journal-title":"Nat. Neurosci."},{"key":"389_CR55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2353\/ajpath.2008.070442","volume":"172","author":"GG Kovacs","year":"2008","unstructured":"Kovacs, G. G. & Budka, H. Prion diseases: from protein to cell pathology. Am. J. Pathol. 172, 555\u2013565 (2008).","journal-title":"Am. J. Pathol."},{"key":"389_CR56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.24174","volume":"76","author":"F Cicchetti","year":"2014","unstructured":"Cicchetti, F. et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann. Neurol. 76, 31\u201342 (2014).","journal-title":"Ann. Neurol."},{"key":"389_CR57","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/MCB.01434-12","volume":"33","author":"JT Lin","year":"2013","unstructured":"Lin, J. T. et al. Regulation of feedback between protein kinase A and the proteasome system worsens Huntington\u2019s disease. Mol. Cell Biol. 33, 1073\u20131084 (2013).","journal-title":"Mol. Cell Biol."},{"key":"389_CR58","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.drudis.2014.02.014","volume":"19","author":"CJ Cortes","year":"2014","unstructured":"Cortes, C. J. & La Spada, A. R. The many faces of autophagy dysfunction in Huntington\u2019s disease: from mechanism to therapy. Drug Discov. Today 19, 963\u2013971 (2014).","journal-title":"Drug Discov. Today"},{"key":"389_CR59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585\u2013595 (2004).","journal-title":"Nat. Genet."},{"key":"389_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.102.035048","volume":"304","author":"B Liu","year":"2003","unstructured":"Liu, B. & Hong, J. S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 1\u20137 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"389_CR61","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/hmg\/ddw262","volume":"25","author":"JR Miller","year":"2016","unstructured":"Miller, J. R. et al. RNA-Seq of Huntington\u2019s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum. Mol. Genet. 25, 2893\u20132904 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/541259","volume":"2013","author":"G Ellrichmann","year":"2013","unstructured":"Ellrichmann, G., Reick, C., Saft, C. & Linker, R. A. The role of the immune system in Huntington\u2019s disease. Clin. Dev. Immunol. 2013, 1\u201311 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"389_CR63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","volume":"12","author":"TH Palpagama","year":"2019","unstructured":"Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M. & Kwakowsky, A. The role of microglia and astrocytes in Huntington\u2019s disease. Front. Mol. Neurosci. 12, 258 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"389_CR64","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1523\/JNEUROSCI.13-10-04181.1993","volume":"13","author":"MF Beal","year":"1993","unstructured":"Beal, M. F. et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181\u20134192 (1993).","journal-title":"J. Neurosci."},{"key":"389_CR65","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/B:NERE.0000014824.04728.dd","volume":"29","author":"SE Browne","year":"2004","unstructured":"Browne, S. E. & Beal, M. F. The energetics of Huntington\u2019s disease. Neurochem. Res. 29, 531\u2013546 (2004).","journal-title":"Neurochem. Res."},{"key":"389_CR66","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mds.25009","volume":"27","author":"F Mochel","year":"2012","unstructured":"Mochel, F. et al. Abnormal response to cortical activation in early stages of Huntington disease. Mov. Disord. 27, 907\u2013910 (2012).","journal-title":"Mov. Disord."},{"key":"389_CR67","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1074\/jbc.M111.309849","volume":"287","author":"F Mochel","year":"2012","unstructured":"Mochel, F. et al. Early alterations of brain cellular energy homeostasis in Huntington disease models. J. Biol. Chem. 287, 1361\u20131370 (2012).","journal-title":"J. Biol. Chem."},{"key":"389_CR68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.28.1.23","volume":"28","author":"HH Goebel","year":"1978","unstructured":"Goebel, H. H., Heipertz, R., Scholz, W., Iqbal, K. & Tellez-Nagel, I. Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 28, 23\u201331 (1978).","journal-title":"Neurology"},{"key":"389_CR69","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1093\/hmg\/ddq306","volume":"19","author":"J Kim","year":"2010","unstructured":"Kim, J. et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington\u2019s disease. Hum. Mol. Genet. 19, 3919\u20133935 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2013.04.016","volume":"62","author":"A Johri","year":"2013","unstructured":"Johri, A., Chandra, A. & Flint Beal, M. PGC-1\u03b1, mitochondrial dysfunction, and Huntington\u2019s disease. Free Radic. Biol. Med. 62, 37\u201346 (2013).","journal-title":"Free Radic. Biol. Med."},{"key":"389_CR71","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410390317","volume":"39","author":"M Gu","year":"1996","unstructured":"Gu, M. et al. Mitochondrial defect in Huntington\u2019s disease caudate nucleus. Ann. Neurol. 39, 385\u2013389 (1996).","journal-title":"Ann. Neurol."},{"key":"389_CR72","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410410514","volume":"41","author":"SE Browne","year":"1997","unstructured":"Browne, S. E. et al. Oxidative damage and metabolic dysfunction in Huntington\u2019s disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646\u2013653 (1997).","journal-title":"Ann. Neurol."},{"key":"389_CR73","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/hmg\/dds503","volume":"22","author":"E Napoli","year":"2013","unstructured":"Napoli, E. et al. Defective mitochondrial disulfide relay system, altered mitochondrial morphology and function in Huntington\u2019s disease. Hum. Mol. Genet. 22, 989\u20131004 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR74","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12035-014-8735-4","volume":"51","author":"L Naia","year":"2015","unstructured":"Naia, L. et al. Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington\u2019s disease human lymphoblasts. Mol. Neurobiol. 51, 331\u2013348 (2015).","journal-title":"Mol. Neurobiol."},{"key":"389_CR75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.brainres.2004.10.030","volume":"1031","author":"NC Reynolds Jr.","year":"2005","unstructured":"Reynolds, N. C. Jr., Prost, R. W. & Mark, L. P. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington\u2019s disease. Brain Res. 1031, 82\u201389 (2005).","journal-title":"Brain Res."},{"key":"389_CR76","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1212\/WNL.43.12.2689","volume":"43","author":"BG Jenkins","year":"1993","unstructured":"Jenkins, B. G., Koroshetz, W. J., Beal, M. F. & Rosen, B. R. Evidence for impairment of energy metabolism in vivo in Huntington\u2019s disease using localized 1H NMR spectroscopy. Neurology 43, 2689\u20132695 (1993).","journal-title":"Neurology"},{"issue":"Pt 6","key":"389_CR77","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","volume":"119","author":"A Antonini","year":"1996","unstructured":"Antonini, A. et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease. Brain 119 (Pt 6), 2085\u20132095 (1996).","journal-title":"Brain"},{"key":"389_CR78","first-page":"1591","volume":"42","author":"A Feigin","year":"2001","unstructured":"Feigin, A. et al. Metabolic network abnormalities in early Huntington\u2019s disease: an [(18)F]FDG PET study. J. Nucl. Med. 42, 1591\u20131595 (2001).","journal-title":"J. Nucl. Med."},{"key":"389_CR79","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1523\/JNEUROSCI.0106-08.2008","volume":"28","author":"AL Orr","year":"2008","unstructured":"Orr, A. L. et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 28, 2783\u20132792 (2008).","journal-title":"J. Neurosci."},{"key":"389_CR80","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","volume":"24","author":"E Trushina","year":"2004","unstructured":"Trushina, E. et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell Biol. 24, 8195\u20138209 (2004).","journal-title":"Mol. Cell Biol."},{"key":"389_CR81","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/hmg\/ddr024","volume":"20","author":"U Shirendeb","year":"2011","unstructured":"Shirendeb, U. et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington\u2019s disease: implications for selective neuronal damage. Hum. Mol. Genet. 20, 1438\u20131455 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR82","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/hmg\/ddr475","volume":"21","author":"UP Shirendeb","year":"2012","unstructured":"Shirendeb, U. P. et al. Mutant huntingtin\u2019s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington\u2019s disease. Hum. Mol. Genet. 21, 406\u2013420 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR83","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","volume":"127","author":"L Cui","year":"2006","unstructured":"Cui, L. et al. Transcriptional repression of PGC-1\u03b1 by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59\u201369 (2006).","journal-title":"Cell"},{"key":"389_CR84","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","volume":"13","author":"YS Choo","year":"2004","unstructured":"Choo, Y. S., Johnson, G. V., MacDonald, M., Detloff, P. J. & Lesort, M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 1407\u20131420 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR85","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","volume":"5","author":"AV Panov","year":"2002","unstructured":"Panov, A. V. et al. Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731\u2013736 (2002).","journal-title":"Nat. Neurosci."},{"key":"389_CR86","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nn.3721","volume":"17","author":"H Yano","year":"2014","unstructured":"Yano, H. et al. Inhibition of mitochondrial protein import by mutant huntingtin. Nat. Neurosci. 17, 822\u2013831 (2014).","journal-title":"Nat. Neurosci."},{"key":"389_CR87","doi-asserted-by":"crossref","first-page":"16593","DOI":"10.1073\/pnas.1904101116","volume":"116","author":"S Yablonska","year":"2019","unstructured":"Yablonska, S. et al. Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23. Proc. Natl Acad. Sci. USA 116, 16593\u201316602 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR88","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bpa.12427","volume":"26","author":"E Marti","year":"2016","unstructured":"Marti, E. RNA toxicity induced by expanded CAG repeats in Huntington\u2019s disease. Brain Pathol. 26, 779\u2013786 (2016).","journal-title":"Brain Pathol."},{"key":"389_CR89","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/nature06909","volume":"453","author":"LB Li","year":"2008","unstructured":"Li, L. B., Yu, Z., Teng, X. & Bonini, N. M. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 453, 1107\u20131111 (2008).","journal-title":"Nature"},{"key":"389_CR90","volume":"6","author":"RJ Hsu","year":"2011","unstructured":"Hsu, R. J. et al. Long tract of untranslated CAG repeats is deleterious in transgenic mice. PLoS ONE 6, e16417 (2011).","journal-title":"PLoS ONE"},{"key":"389_CR91","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00018-010-0522-4","volume":"68","author":"LC Wang","year":"2011","unstructured":"Wang, L. C. et al. Muscleblind participates in RNA toxicity of expanded CAG and CUG repeats in Caenorhabditis elegans. Cell Mol. Life Sci. 68, 1255\u20131267 (2011).","journal-title":"Cell Mol. Life Sci."},{"key":"389_CR92","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.neuron.2015.10.038","volume":"88","author":"M Banez-Coronel","year":"2015","unstructured":"Banez-Coronel, M. et al. RAN translation in Huntington disease. Neuron 88, 667\u2013677 (2015).","journal-title":"Neuron"},{"key":"389_CR93","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.cell.2017.10.042","volume":"171","author":"FB Gao","year":"2017","unstructured":"Gao, F. B., Richter, J. D. & Cleveland, D. W. Rethinking unconventional translation in neurodegeneration. Cell 171, 994\u20131000 (2017).","journal-title":"Cell"},{"key":"389_CR94","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1073\/pnas.1919197117","volume":"117","author":"S Yang","year":"2020","unstructured":"Yang, S. et al. Lack of RAN-mediated toxicity in Huntington\u2019s disease knock-in mice. Proc. Natl Acad. Sci. USA 117, 4411\u20134417 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR95","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","volume":"12","author":"L Kennedy","year":"2003","unstructured":"Kennedy, L. et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum. Mol. Genet. 12, 3359\u20133367 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR96","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/hmg\/ddm054","volume":"16","author":"PF Shelbourne","year":"2007","unstructured":"Shelbourne, P. F. et al. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum. Mol. Genet. 16, 1133\u20131142 (2007).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR97","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1093\/hmg\/ddp242","volume":"18","author":"M Swami","year":"2009","unstructured":"Swami, M. et al. Somatic expansion of the Huntington\u2019s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum. Mol. Genet. 18, 3039\u20133047 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR98","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","volume":"178","author":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) consortium","year":"2019","unstructured":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) consortium. CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset. Cell 178, 887\u2013900.e14 (2019).","journal-title":"Cell"},{"key":"389_CR99","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/hmg\/2.10.1535","volume":"2","author":"H Telenius","year":"1993","unstructured":"Telenius, H. et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum. Mol. Genet. 2, 1535\u20131540 (1993).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR100","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/0896-6273(95)90106-X","volume":"15","author":"N Aronin","year":"1995","unstructured":"Aronin, N. et al. CAG expansion affects the expression of mutant huntingtin in the Huntington\u2019s disease brain. Neuron 15, 1193\u20131201 (1995).","journal-title":"Neuron"},{"key":"389_CR101","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/WNL.51.5.1442","volume":"51","author":"T Ansved","year":"1998","unstructured":"Ansved, T., Lundin, A. & Anvret, M. Larger CAG expansions in skeletal muscle compared with lymphocytes in Kennedy disease but not in Huntington disease. Neurology 51, 1442\u20131444 (1998).","journal-title":"Neurology"},{"key":"389_CR102","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1468-1331.2006.01264.x","volume":"13","author":"F Squitieri","year":"2006","unstructured":"Squitieri, F., Ciarmiello, A., Di Donato, S. & Frati, L. The search for cerebral biomarkers of Huntington\u2019s disease: a review of genetic models of age at onset prediction. Eur. J. Neurol. 13, 408\u2013415 (2006).","journal-title":"Eur. J. Neurol."},{"key":"389_CR103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.0030235","volume":"3","author":"S Kaplan","year":"2007","unstructured":"Kaplan, S., Itzkovitz, S. & Shapiro, E. A universal mechanism ties genotype to phenotype in trinucleotide diseases. PLoS Comput. Biol. 3, e235 (2007).","journal-title":"PLoS Comput. Biol."},{"key":"389_CR104","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1750-3639.1997.tb00895.x","volume":"7","author":"AR La Spada","year":"1997","unstructured":"La Spada, A. R. Trinucleotide repeat instability: genetic features and molecular mechanisms. Brain Pathol. 7, 943\u2013963 (1997).","journal-title":"Brain Pathol."},{"key":"389_CR105","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ajhg.2019.04.007","volume":"104","author":"GEB Wright","year":"2019","unstructured":"Wright, G. E. B. et al. Length of uninterrupted CAG repeats, independent of polyglutamine size, results in increased somatic instability and hastened age of onset in Huntington disease. Am. J. Hum. Genet.104, 1116\u20131126 (2019).","journal-title":"Am. J. Hum. Genet."},{"key":"389_CR106","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/mds.26001","volume":"29","author":"JF Gusella","year":"2014","unstructured":"Gusella, J. F., MacDonald, M. E. & Lee, J. M. Genetic modifiers of Huntington\u2019s disease. Mov. Disord. 29, 1359\u20131365 (2014).","journal-title":"Mov. Disord."},{"key":"389_CR107","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler, N. S. et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. Proc. Natl Acad. Sci. USA 101, 3498\u20133503 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR108","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) consortium","year":"2015","unstructured":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) consortium. Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell 162, 516\u2013526 (2015).","journal-title":"Cell"},{"key":"389_CR109","volume":"8","author":"A Porro","year":"2017","unstructured":"Porro, A. et al. FAN1 interaction with ubiquitylated PCNA alleviates replication stress and preserves genomic integrity independently of BRCA2. Nat. Commun. 8, 1073 (2017).","journal-title":"Nat. Commun."},{"key":"389_CR110","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/hmg\/ddy375","volume":"28","author":"R Goold","year":"2018","unstructured":"Goold, R. et al. FAN1 modifies Huntington\u2019s disease progression by stabilising the expanded HTT CAG repeat. Hum. Mol. Genet. 28, 650\u2013661 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2018.07.001","volume":"69","author":"XN Zhao","year":"2018","unstructured":"Zhao, X. N. & Usdin, K. FAN1 protects against repeat expansions in a fragile X mouse model. DNA Repair 69, 1\u20135 (2018).","journal-title":"DNA Repair"},{"key":"389_CR112","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fnmol.2014.00077","volume":"7","author":"Z Ortega","year":"2014","unstructured":"Ortega, Z. & Lucas, J. J. Ubiquitin-proteasome system involvement in Huntington\u2019s disease. Front. Mol. Neurosci. 7, 77 (2014).","journal-title":"Front. Mol. Neurosci."},{"key":"389_CR113","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05320-3","volume":"9","author":"S Koyuncu","year":"2018","unstructured":"Koyuncu, S. et al. The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent stem cells from Huntington\u2019s disease patients. Nat. Commun. 9, 2886 (2018).","journal-title":"Nat. Commun."},{"key":"389_CR114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003930","volume":"9","author":"RM Pinto","year":"2013","unstructured":"Pinto, R. M. et al. Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington\u2019s disease mice: genome-wide and candidate approaches. PLoS Genet. 9, e1003930 (2013).","journal-title":"PLoS Genet."},{"key":"389_CR115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","volume":"16","author":"DJH Hensman Moss","year":"2017","unstructured":"Hensman Moss, D. J. H. et al. Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study. Lancet. Neurol. 16, 701\u2013711 (2017).","journal-title":"Lancet. Neurol."},{"key":"389_CR116","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-biochem-060614-034010","volume":"84","author":"RR Iyer","year":"2015","unstructured":"Iyer, R. R., Pluciennik, A., Napierala, M. & Wells, R. D. DNA triplet repeat expansion and mismatch repair. Annu. Rev. Biochem. 84, 199\u2013226 (2015).","journal-title":"Annu. Rev. Biochem."},{"key":"389_CR117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2008.09.014","volume":"33","author":"E Dragileva","year":"2009","unstructured":"Dragileva, E. et al. Intergenerational and striatal CAG repeat instability in Huntington\u2019s disease knock-in mice involve different DNA repair genes. Neurobiol. Dis. 33, 37\u201347 (2009).","journal-title":"Neurobiol. Dis."},{"key":"389_CR118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003280","volume":"9","author":"S Tome","year":"2013","unstructured":"Tome, S. et al. MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington\u2019s disease mice. PLoS Genet. 9, e1003280 (2013).","journal-title":"PLoS Genet."},{"key":"389_CR119","doi-asserted-by":"crossref","first-page":"15163","DOI":"10.1073\/pnas.1103623108","volume":"108","author":"DD Anderson","year":"2011","unstructured":"Anderson, D. D., Quintero, C. M. & Stover, P. J. Identification of a de novo thymidylate biosynthesis pathway in mammalian mitochondria. Proc. Natl Acad. Sci. USA 108, 15163\u201315168 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR120","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/brain\/awz115","volume":"142","author":"M Flower","year":"2019","unstructured":"Flower, M. et al. MSH3 modifies somatic instability and disease severity in Huntington\u2019s and myotonic dystrophy type 1. Brain 142, 1876\u20131886 (2019).","journal-title":"Brain"},{"key":"389_CR121","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/jmg.2006.045153","volume":"44","author":"JM Andresen","year":"2007","unstructured":"Andresen, J. M. et al. Replication of twelve association studies for Huntington\u2019s disease residual age of onset in large Venezuelan kindreds. J. Med. Genet. 44, 44\u201350 (2007).","journal-title":"J. Med. Genet."},{"key":"389_CR122","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1073\/pnas.98.4.1811","volume":"98","author":"S Holbert","year":"2001","unstructured":"Holbert, S. et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington\u2019s disease pathogenesis. Proc. Natl Acad. Sci. USA 98, 1811\u20131816 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR123","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1074\/mcp.M115.055723","volume":"15","author":"SV Kozlov","year":"2016","unstructured":"Kozlov, S. V. et al. Reactive oxygen species (ROS)-activated ATM-dependent phosphorylation of cytoplasmic substrates identified by large-scale phosphoproteomics screen. Mol. Cell. Proteomics 15, 1032\u20131047 (2016).","journal-title":"Mol. Cell. Proteomics"},{"key":"389_CR124","doi-asserted-by":"crossref","first-page":"dmm031930","DOI":"10.1242\/dmm.031930","volume":"11","author":"TH Massey","year":"2018","unstructured":"Massey, T. H. & Jones, L. The central role of DNA damage and repair in CAG repeat diseases. Dis. Model. Mech. 11, dmm031930 (2018).","journal-title":"Dis. Model. Mech."},{"key":"389_CR125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/978-94-007-4572-8_17","volume":"62","author":"TR Howes","year":"2012","unstructured":"Howes, T. R. & Tomkinson, A. E. DNA ligase I, the replicative DNA ligase. Subcell. Biochem. 62, 327\u2013341 (2012).","journal-title":"Subcell. Biochem."},{"key":"389_CR126","doi-asserted-by":"crossref","first-page":"26631","DOI":"10.1074\/jbc.M109.034405","volume":"284","author":"A Lopez Castel","year":"2009","unstructured":"Lopez Castel, A., Tomkinson, A. E. & Pearson, C. E. CTG\/CAG repeat instability is modulated by the levels of human DNA ligase I and its interaction with proliferating cell nuclear antigen: a distinction between replication and slipped-DNA repair. J. Biol. Chem. 284, 26631\u201326645 (2009).","journal-title":"J. Biol. Chem."},{"key":"389_CR127","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/hmg\/ddr099","volume":"20","author":"S Tome","year":"2011","unstructured":"Tome, S. et al. Maternal germline-specific effect of DNA ligase I on CTG\/CAG instability. Hum. Mol. Genet. 20, 2131\u20132143 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR128","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/hmg\/ddh186","volume":"13","author":"M Gomes-Pereira","year":"2004","unstructured":"Gomes-Pereira, M., Fortune, M. T., Ingram, L., McAbney, J. P. & Monckton, D. G. Pms2 is a genetic enhancer of trinucleotide CAG.CTG repeat somatic mosaicism: implications for the mechanism of triplet repeat expansion. Hum. Mol. Genet. 13, 1815\u20131825 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR129","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ana.24656","volume":"79","author":"C Bettencourt","year":"2016","unstructured":"Bettencourt, C. et al. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Ann. Neurol. 79, 983\u2013990 (2016).","journal-title":"Ann. Neurol."},{"key":"389_CR130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.dnarep.2016.01.001","volume":"40","author":"F Morales","year":"2016","unstructured":"Morales, F. et al. A polymorphism in the MSH3 mismatch repair gene is associated with the levels of somatic instability of the expanded CTG repeat in the blood DNA of myotonic dystrophy type 1 patients. DNA Repair 40, 57\u201366 (2016).","journal-title":"DNA Repair"},{"key":"389_CR131","doi-asserted-by":"crossref","DOI":"10.1038\/srep11020","volume":"5","author":"R Nakatani","year":"2015","unstructured":"Nakatani, R., Nakamori, M., Fujimura, H., Mochizuki, H. & Takahashi, M. P. Large expansion of CTG\u2022CAG repeats is exacerbated by MutS\u03b2 in human cells. Sci. Rep. 5, 11020 (2015).","journal-title":"Sci. Rep."},{"key":"389_CR132","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1093\/nar\/gky143","volume":"46","author":"A Halabi","year":"2018","unstructured":"Halabi, A., Fuselier, K. T. B. & Grabczyk, E. GAA\u2022TTC repeat expansion in human cells is mediated by mismatch repair complex MutL\u03b3 and depends upon the endonuclease domain in MLH3 isoform one. Nucleic Acids Res. 46, 4022\u20134032 (2018).","journal-title":"Nucleic Acids Res."},{"key":"389_CR133","doi-asserted-by":"crossref","first-page":"41844","DOI":"10.1074\/jbc.M112.420398","volume":"287","author":"GB Panigrahi","year":"2012","unstructured":"Panigrahi, G. B., Slean, M. M., Simard, J. P. & Pearson, C. E. Human mismatch repair protein hMutL is required to repair short slipped-DNAs of trinucleotide repeats. J. Biol. Chem. 287, 41844\u201341850 (2012).","journal-title":"J. Biol. Chem."},{"key":"389_CR134","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nsmb1042","volume":"13","author":"Y Lin","year":"2006","unstructured":"Lin, Y., Dion, V. & Wilson, J. H. Transcription promotes contraction of CAG repeat tracts in human cells. Nat. Struct. Mol. Biol. 13, 179\u2013180 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"389_CR135","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.dnarep.2009.04.024","volume":"8","author":"Y Lin","year":"2009","unstructured":"Lin, Y. & Wilson, J. H. Diverse effects of individual mismatch repair components on transcription-induced CAG repeat instability in human cells. DNA Repair 8, 878\u2013885 (2009).","journal-title":"DNA Repair"},{"key":"389_CR136","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1093\/nar\/gks810","volume":"40","author":"AM Gannon","year":"2012","unstructured":"Gannon, A. M., Frizzell, A., Healy, E. & Lahue, R. S. MutSbeta and histone deacetylase complexes promote expansions of trinucleotide repeats in human cells. Nucleic Acids Res. 40, 10324\u201310333 (2012).","journal-title":"Nucleic Acids Res."},{"key":"389_CR137","doi-asserted-by":"crossref","first-page":"10068","DOI":"10.1093\/nar\/gkx650","volume":"45","author":"N Keogh","year":"2017","unstructured":"Keogh, N., Chan, K. Y., Li, G. M. & Lahue, R. S. MutS\u03b2 abundance and Msh3 ATP hydrolysis activity are important drivers of CTG*CAG repeat expansions. Nucleic Acids Res. 45, 10068\u201310078 (2017).","journal-title":"Nucleic Acids Res."},{"key":"389_CR138","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/hmg\/ddq456","volume":"20","author":"A Seriola","year":"2011","unstructured":"Seriola, A. et al. Huntington\u2019s and myotonic dystrophy hESCs: down-regulated trinucleotide repeat instability and mismatch repair machinery expression upon differentiation. Hum. Mol. Genet. 20, 176\u2013185 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR139","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1093\/hmg\/ddt386","volume":"22","author":"J Du","year":"2013","unstructured":"Du, J., Campau, E., Soragni, E., Jespersen, C. & Gottesfeld, J. M. Length-dependent CTG.CAG triplet-repeat expansion in myotonic dystrophy patient-derived induced pluripotent stem cells. Hum. Mol. Genet. 22, 5276\u20135287 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003866","volume":"9","author":"MM Axford","year":"2013","unstructured":"Axford, M. M. et al. Detection of slipped-DNAs at the trinucleotide repeats of the myotonic dystrophy type I disease locus in patient tissues. PLoS Genet. 9, e1003866 (2013).","journal-title":"PLoS Genet."},{"key":"389_CR141","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.dnarep.2015.11.008","volume":"38","author":"MH Schmidt","year":"2016","unstructured":"Schmidt, M. H. & Pearson, C. E. Disease-associated repeat instability and mismatch repair. DNA Repair 38, 117\u2013126 (2016).","journal-title":"DNA Repair"},{"key":"389_CR142","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11888-017-0352-y","volume":"13","author":"JM Carethers","year":"2017","unstructured":"Carethers, J. M. Microsatellite instability pathway and EMAST in colorectal cancer. Curr. Colorectal Cancer Rep. 13, 73\u201380 (2017).","journal-title":"Curr. Colorectal Cancer Rep."},{"key":"389_CR143","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0092-8674(95)90074-8","volume":"81","author":"AM Gacy","year":"1995","unstructured":"Gacy, A. M., Goellner, G., Juranic, N., Macura, S. & McMurray, C. T. Trinucleotide repeats that expand in human disease form hairpin structures in vitro. Cell 81, 533\u2013540 (1995).","journal-title":"Cell"},{"key":"389_CR144","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1073\/pnas.0800048105","volume":"105","author":"R Gonitel","year":"2008","unstructured":"Gonitel, R. et al. DNA instability in postmitotic neurons. Proc. Natl Acad. Sci. USA 105, 3467\u20133472 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR145","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1093\/nar\/gku285","volume":"42","author":"M Gomes-Pereira","year":"2014","unstructured":"Gomes-Pereira, M. et al. Disease-associated CAG\u00b7CTG triplet repeats expand rapidly in non-dividing mouse cells, but cell cycle arrest is insufficient to drive expansion. Nucleic Acids Res. 42, 7047\u20137056 (2014).","journal-title":"Nucleic Acids Res."},{"key":"389_CR146","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.dnarep.2016.04.002","volume":"42","author":"MM Slean","year":"2016","unstructured":"Slean, M. M. et al. Absence of MutS\u03b2 leads to the formation of slipped-DNA for CTG\/CAG contractions at primate replication forks. DNA Repair 42, 107\u2013118 (2016).","journal-title":"DNA Repair"},{"key":"389_CR147","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nchembio.416","volume":"6","author":"G Liu","year":"2010","unstructured":"Liu, G., Chen, X., Bissler, J. J., Sinden, R. R. & Leffak, M. Replication-dependent instability at (CTG)\u2022(CAG) repeat hairpins in human cells. Nat. Chem. Biol. 6, 652\u2013659 (2010).","journal-title":"Nat. Chem. Biol."},{"key":"389_CR148","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cca.2015.01.014","volume":"442","author":"Y Muro","year":"2015","unstructured":"Muro, Y., Sugiura, K., Mimori, T. & Akiyama, M. DNA mismatch repair enzymes: genetic defects and autoimmunity. Clinica Chim. Acta. 442, 102\u2013109 (2015).","journal-title":"Clinica Chim. Acta."},{"key":"389_CR149","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/genes5030497","volume":"5","author":"R Sehgal","year":"2014","unstructured":"Sehgal, R. et al. Lynch syndrome: an updated review. Genes 5, 497\u2013507 (2014).","journal-title":"Genes"},{"key":"389_CR150","doi-asserted-by":"crossref","first-page":"D1005","DOI":"10.1093\/nar\/gky1120","volume":"47","author":"A Buniello","year":"2019","unstructured":"Buniello, A. et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005\u2013D1012 (2019).","journal-title":"Nucleic Acids Res."},{"key":"389_CR151","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.neuron.2016.03.016","volume":"90","author":"J Ochaba","year":"2016","unstructured":"Ochaba, J. et al. PIAS1 regulates mutant huntingtin accumulation and Huntington\u2019s disease-associated phenotypes in vivo. Neuron 90, 507\u2013520 (2016).","journal-title":"Neuron"},{"key":"389_CR152","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"389_CR153","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/hmg\/2.10.1541","volume":"2","author":"B Lin","year":"1993","unstructured":"Lin, B. et al. Differential 3\u2032 polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Hum. Mol. Genet. 2, 1541\u20131545 (1993).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR154","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M109.075028","volume":"285","author":"C Landles","year":"2010","unstructured":"Landles, C. et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in huntington disease. J. Biol. Chem. 285, 8808\u20138823 (2010).","journal-title":"J. Biol. Chem."},{"key":"389_CR155","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","volume":"7","author":"A Neueder","year":"2017","unstructured":"Neueder, A. et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington\u2019s disease patients. Sci. Rep. 7, 1307\u20131307 (2017).","journal-title":"Sci. Rep."},{"key":"389_CR156","doi-asserted-by":"crossref","unstructured":"Bates, G., Tabrizi, S. & Jones, L. Huntington\u2019s Disease (Oxford University Press, 2014).","DOI":"10.1093\/med\/9780199929146.001.0001"},{"key":"389_CR157","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrm.2016.147","volume":"18","author":"M Beck","year":"2017","unstructured":"Beck, M. & Hurt, E. The nuclear pore complex: understanding its function through structural insight. Nat. Rev. Mol. Cell Biol. 18, 73\u201389 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"389_CR158","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ana.20902","volume":"60","author":"L Basel-Vanagaite","year":"2006","unstructured":"Basel-Vanagaite, L. et al. Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis. Ann. Neurol. 60, 214\u2013222 (2006).","journal-title":"Ann. Neurol."},{"key":"389_CR159","first-page":"82","volume":"3","author":"T Cavazza","year":"2015","unstructured":"Cavazza, T. & Vernos, I. The RanGTP pathway: from nucleo-cytoplasmic transport to spindle assembly and beyond. Front. Cell Dev. Biol. 3, 82 (2015).","journal-title":"Front. Cell Dev. Biol."},{"key":"389_CR160","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1038\/ncb0702-e177","volume":"4","author":"M Hetzer","year":"2002","unstructured":"Hetzer, M., Gruss, O. J. & Mattaj, I. W. The Ran GTPase as a marker of chromosome position in spindle formation and nuclear envelope assembly. Nat. Cell Biol. 4, E177\u2013E184 (2002).","journal-title":"Nat. Cell Biol."},{"key":"389_CR161","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.celrep.2015.04.030","volume":"11","author":"F Hosp","year":"2015","unstructured":"Hosp, F. et al. Quantitative interaction proteomics of neurodegenerative disease proteins. Cell Rep. 11, 1134\u20131146 (2015).","journal-title":"Cell Rep."},{"key":"389_CR162","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neuron.2017.03.023","volume":"94","author":"JC Grima","year":"2017","unstructured":"Grima, J. C. et al. Mutant huntingtin disrupts the nuclear pore complex. Neuron 94, 93\u2013107.e6 (2017).","journal-title":"Neuron"},{"key":"389_CR163","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nn.4272","volume":"19","author":"YJ Zhang","year":"2016","unstructured":"Zhang, Y. J. et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 19, 668\u2013677 (2016).","journal-title":"Nat. Neurosci."},{"key":"389_CR164","doi-asserted-by":"crossref","first-page":"E1111","DOI":"10.1073\/pnas.1620293114","volume":"114","author":"KY Shi","year":"2017","unstructured":"Shi, K. Y. et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc. Natl Acad. Sci. USA 114, E1111\u2013E1117 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12195-016-0440-0","volume":"9","author":"A Ruba","year":"2016","unstructured":"Ruba, A. & Yang, W. O-GlcNAc-ylation in the nuclear pore complex. Cell Mol. Bioeng. 9, 227\u2013233 (2016).","journal-title":"Cell Mol. Bioeng."},{"key":"389_CR166","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nn.3953","volume":"18","author":"JD Haines","year":"2015","unstructured":"Haines, J. D. et al. Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination. Nat. Neurosci. 18, 511\u2013520 (2015).","journal-title":"Nat. Neurosci."},{"key":"389_CR167","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature14973","volume":"525","author":"K Zhang","year":"2015","unstructured":"Zhang, K. et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56\u201361 (2015).","journal-title":"Nature"},{"key":"389_CR168","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22858-w","volume":"8","author":"HC Archbold","year":"2018","unstructured":"Archbold, H. C. et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci. Rep. 8, 4606 (2018).","journal-title":"Sci. Rep."},{"key":"389_CR169","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature25502","volume":"555","author":"Q Guo","year":"2018","unstructured":"Guo, Q. et al. The cryo-electron microscopy structure of huntingtin. Nature 555, 117\u2013120 (2018).","journal-title":"Nature"},{"key":"389_CR170","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1074\/jbc.M008099200","volume":"276","author":"MF Peters","year":"2001","unstructured":"Peters, M. F. & Ross, C. A. Isolation of a 40-kDa huntingtin-associated protein. J. Biol. Chem. 276, 3188\u20133194 (2001).","journal-title":"J. Biol. Chem."},{"key":"389_CR171","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1083\/jcb.200509091","volume":"172","author":"A Pal","year":"2006","unstructured":"Pal, A., Severin, F., Lommer, B., Shevchenko, A. & Zerial, M. Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington\u2019s disease. J. Cell Biol. 172, 605\u2013618 (2006).","journal-title":"J. Cell Biol."},{"key":"389_CR172","doi-asserted-by":"crossref","first-page":"15916","DOI":"10.1074\/jbc.M511007200","volume":"281","author":"W Li","year":"2006","unstructured":"Li, W., Serpell, L. C., Carter, W. J., Rubinsztein, D. C. & Huntington, J. A. Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein. J. Biol. Chem. 281, 15916\u201315922 (2006).","journal-title":"J. Biol. Chem."},{"key":"389_CR173","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ng1095-115","volume":"11","author":"MA Andrade","year":"1995","unstructured":"Andrade, M. A. & Bork, P. HEAT repeats in the Huntington\u2019s disease protein. Nat. Genet. 11, 115\u2013116 (1995).","journal-title":"Nat. Genet."},{"key":"389_CR174","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/hmg\/ddp524","volume":"19","author":"IS Seong","year":"2010","unstructured":"Seong, I. S. et al. Huntingtin facilitates polycomb repressive complex 2. Hum. Mol. Genet. 19, 573\u2013583 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR175","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1021\/acs.jproteome.6b00991","volume":"16","author":"T Ratovitski","year":"2017","unstructured":"Ratovitski, T. et al. Post-translational modifications (PTMs), identified on endogenous huntingtin, cluster within proteolytic domains between HEAT repeats. J. Proteome Res. 16, 2692\u20132708 (2017).","journal-title":"J. Proteome Res."},{"key":"389_CR176","doi-asserted-by":"crossref","first-page":"19238","DOI":"10.1074\/jbc.M117.782300","volume":"292","author":"N Arbez","year":"2017","unstructured":"Arbez, N. et al. Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity. J. Biol. Chem. 292, 19238\u201319249 (2017).","journal-title":"J. Biol. Chem."},{"key":"389_CR177","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4155\/bio-2018-0006","volume":"10","author":"LM Yee","year":"2018","unstructured":"Yee, L. M., Lively, T. G. & McShane, L. M. Biomarkers in early-phase trials: fundamental issues. Bioanalysis 10, 933\u2013944 (2018).","journal-title":"Bioanalysis"},{"key":"389_CR178","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-4939-7825-0_17","volume":"1780","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues, F. B., Byrne, L. M. & Wild, E. J. Biofluid biomarkers in Huntington\u2019s disease. Methods Mol. Biol. 1780, 329\u2013396 (2018).","journal-title":"Methods Mol. Biol."},{"key":"389_CR179","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JHD-170273","volume":"7","author":"E Silajdzic","year":"2018","unstructured":"Silajdzic, E. & Bjorkqvist, M. A critical evaluation of wet biomarkers for Huntington\u2019s disease: current status and ways forward. J. Huntington\u2019s Dis. 7, 109\u2013135 (2018).","journal-title":"J. Huntington\u2019s Dis."},{"key":"389_CR180","doi-asserted-by":"crossref","DOI":"10.1038\/srep12166","volume":"5","author":"AL Southwell","year":"2015","unstructured":"Southwell, A. L. et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci. Rep. 5, 12166 (2015).","journal-title":"Sci. Rep."},{"key":"389_CR181","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild, E. J. et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J. Clin. Invest. 125, 1979\u20131986 (2015).","journal-title":"J. Clin. Invest."},{"key":"389_CR182","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JHD-170269","volume":"6","author":"V Fodale","year":"2017","unstructured":"Fodale, V. et al. Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay. J. Huntington\u2019s Dis. 6, 349\u2013361 (2017).","journal-title":"J. Huntington\u2019s Dis."},{"key":"389_CR183","doi-asserted-by":"crossref","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"LM Byrne","year":"2018","unstructured":"Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci. Transl Med. 10, eaat7108 (2018).","journal-title":"Sci. Transl Med."},{"key":"389_CR184","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N. Engl. J. Med. 380, 2307\u20132316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"389_CR185","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/WNL.0000000000003912","volume":"88","author":"P Shahim","year":"2017","unstructured":"Shahim, P., Zetterberg, H., Tegner, Y. & Blennow, K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88, 1788\u20131794 (2017).","journal-title":"Neurology"},{"key":"389_CR186","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.parkreldis.2008.05.012","volume":"15","author":"R Constantinescu","year":"2009","unstructured":"Constantinescu, R., Romer, M., Oakes, D., Rosengren, L. & Kieburtz, K. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington\u2019s disease. Parkinsonism Relat. Disord. 15, 245\u2013248 (2009).","journal-title":"Parkinsonism Relat. Disord."},{"key":"389_CR187","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000287","volume":"3","author":"T Vinther-Jensen","year":"2016","unstructured":"Vinther-Jensen, T. et al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol. Neuroimmunol. Neuroinflamm. 3, e287 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"389_CR188","volume":"12","author":"V Niemel\u00e4","year":"2017","unstructured":"Niemel\u00e4, V., Landtblom, A.-M., Blennow, K. & Sundblom, J. Tau or neurofilament light \u2014 which is the more suitable biomarker for Huntington\u2019s disease? PLoS ONE 12, e0172762 (2017).","journal-title":"PLoS ONE"},{"key":"389_CR189","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet. Neurol. 16, 601\u2013609 (2017).","journal-title":"Lancet. Neurol."},{"key":"389_CR190","volume":"11","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues, F. B. et al. Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington\u2019s disease. PLoS ONE 11, e0163479 (2016).","journal-title":"PLoS ONE"},{"key":"389_CR191","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14179-1","volume":"7","author":"R Soylu-Kucharz","year":"2017","unstructured":"Soylu-Kucharz, R. et al. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington\u2019s disease R6\/2 mice. Sci. Rep. 7, 14114 (2017).","journal-title":"Sci. Rep."},{"key":"389_CR192","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1212\/WNL.0000000000005005","volume":"90","author":"EB Johnson","year":"2018","unstructured":"Johnson, E. B. et al. Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology 90, e717\u2013e723 (2018).","journal-title":"Neurology"},{"key":"389_CR193","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.parkreldis.2014.08.011","volume":"20","author":"T Vinther-Jensen","year":"2014","unstructured":"Vinther-Jensen, T., Budtz-Jorgensen, E., Simonsen, A. H., Nielsen, J. E. & Hjermind, L. E. YKL-40 in cerebrospinal fluid in Huntington\u2019s disease\u2013a role in pathology or a nonspecific response to inflammation? Parkinsonism Relat. Disord. 20, 1301\u20131303 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"389_CR194","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","volume":"139","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues, F. B. et al. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease. J. Neurochem. 139, 22\u201325 (2016).","journal-title":"J. Neurochem."},{"key":"389_CR195","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JHD-140111","volume":"3","author":"MY Davis","year":"2014","unstructured":"Davis, M. Y., Keene, C. D., Jayadev, S. & Bird, T. The co-occurrence of Alzheimer\u2019s disease and Huntington\u2019s disease: a neuropathological study of 15 elderly Huntington\u2019s disease subjects. J. Huntington\u2019s Dis. 3, 209\u2013217 (2014).","journal-title":"J. Huntington\u2019s Dis."},{"key":"389_CR196","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s007020050095","volume":"105","author":"KA Jellinger","year":"1998","unstructured":"Jellinger, K. A. Alzheimer-type lesions in Huntington\u2019s disease. J. Neural Transm. 105, 787\u2013799 (1998).","journal-title":"J. Neural Transm."},{"key":"389_CR197","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","volume":"138","author":"R Vuono","year":"2015","unstructured":"Vuono, R. et al. The role of tau in the pathological process and clinical expression of Huntington\u2019s disease. Brain 138, 1907\u20131918 (2015).","journal-title":"Brain"},{"key":"389_CR198","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","volume":"135","author":"I St-Amour","year":"2018","unstructured":"St-Amour, I., Turgeon, A., Goupil, C., Planel, E. & Hebert, S. S. Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease. Acta Neuropathol. 135, 249\u2013265 (2018).","journal-title":"Acta Neuropathol."},{"key":"389_CR199","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nm.3617","volume":"20","author":"M Fernandez-Nogales","year":"2014","unstructured":"Fernandez-Nogales, M. et al. Huntington\u2019s disease is a four-repeat tauopathy with tau nuclear rods. Nat. Med. 20, 881\u2013885 (2014).","journal-title":"Nat. Med."},{"key":"389_CR200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/hmg\/ddu421","volume":"24","author":"D Blum","year":"2015","unstructured":"Blum, D. et al. Mutant huntingtin alters tau phosphorylation and subcellular distribution. Hum. Mol. Genet. 24, 76\u201385 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR201","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41374-018-0166-9","volume":"99","author":"SU Baskota","year":"2019","unstructured":"Baskota, S. U., Lopez, O. L., Greenamyre, J. T. & Kofler, J. Spectrum of tau pathologies in Huntington\u2019s disease. Lab. Invest. 99, 1068\u20131077 (2019).","journal-title":"Lab. Invest."},{"key":"389_CR202","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03225846 (2020)."},{"key":"389_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03225833 (2020)."},{"key":"389_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761849 (2020)."},{"key":"389_CR205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan, P. & Tabrizi, S. J. Huntington\u2019s disease: a clinical review. Eur. J. Neurol. 25, 24\u201334 (2018).","journal-title":"Eur. J. Neurol."},{"key":"389_CR206","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/21678707.2016.1196128","volume":"4","author":"C Est\u00e9vez-Fraga","year":"2016","unstructured":"Est\u00e9vez-Fraga, C., Avil\u00e9s Olmos, I., Ma\u00f1anes Barral, V. & L\u00f3pez-Send\u00f3n Moreno, J. L. Therapeutic advances in Huntington\u2019s disease. Expert Opin. Orphan Drugs 4, 809\u2013821 (2016).","journal-title":"Expert Opin. Orphan Drugs"},{"key":"389_CR207","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","volume":"18","author":"R Reilmann","year":"2019","unstructured":"Reilmann, R. et al. Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 18, 165\u2013176 (2019).","journal-title":"Lancet Neurol."},{"key":"389_CR208","unstructured":"US National Library of Medicine. Randomized, placebo controlled study of the efficacy and safety of PF-02545920 in subjects with Huntington\u2019s disease. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02197130 (2017)."},{"key":"389_CR209","unstructured":"Delnomdedieu, M. PDE10i and HD: learnings from the Amaryllis studies Presented at The CHDI 13th Annual HD Therapeutics Conference. https:\/\/chdifoundation.org\/2018-conference (2018)."},{"key":"389_CR210","unstructured":"Wild, E. C. J. Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington\u2019s disease symptoms https:\/\/en.hdbuzz.net\/229 (2016)."},{"key":"389_CR211","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","volume":"88","author":"A McGarry","year":"2017","unstructured":"McGarry, A. et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88, 152\u2013159 (2017).","journal-title":"Neurology"},{"key":"389_CR212","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","volume":"57","author":"Huntington Study Group","year":"2001","unstructured":"Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease. Neurology 57, 397\u2013404 (2001).","journal-title":"Neurology"},{"key":"389_CR213","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","volume":"89","author":"SM Hersch","year":"2017","unstructured":"Hersch, S. M. et al. The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology 89, 594\u2013601 (2017).","journal-title":"Neurology"},{"key":"389_CR214","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.27010","volume":"32","author":"C Verny","year":"2017","unstructured":"Verny, C. et al. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington\u2019s disease. Mov. Disord. 32, 932\u2013936 (2017).","journal-title":"Mov. Disord."},{"key":"389_CR215","doi-asserted-by":"crossref","first-page":"S47.004","DOI":"10.1212\/WNL.82.10_supplement.S47.004","volume":"82","author":"R Reilmann","year":"2014","unstructured":"Reilmann, R. et al. Safety and tolerability of selisistat for the treatment of Huntington\u2019s disease: results from a randomized, double-blind, placebo-controlled phase II trial [abstract]. Neurology 82, S47.004 (2014).","journal-title":"Neurology"},{"key":"389_CR216","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcp.12512","volume":"79","author":"SD S\u00fcssmuth","year":"2015","unstructured":"S\u00fcssmuth, S. D. et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease. Br. J. Clin. Pharmacol. 79, 465\u2013476 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"389_CR217","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","volume":"14","author":"Huntington Study Group Reach2HD Investigators","year":"2015","unstructured":"Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 39\u201347 (2015).","journal-title":"Lancet Neurol."},{"key":"389_CR218","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"JL Lopez-Sendon Moreno","year":"2016","unstructured":"Lopez-Sendon Moreno, J. L. et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with sativex in Huntington\u2019s disease. J. Neurol. 263, 1390\u20131400 (2016).","journal-title":"J. Neurol."},{"key":"389_CR219","unstructured":"Active Biotech. Active Biotech provides update on laquinimod in Huntington\u2019s disease. http:\/\/hugin.info\/1002\/R\/2208124\/858841.pdf (2018)."},{"key":"389_CR220","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1073\/pnas.0904239106","volume":"106","author":"F Cicchetti","year":"2009","unstructured":"Cicchetti, F. et al. Neural transplants in patients with Huntington\u2019s disease undergo disease-like neuronal degeneration. Proc. Natl Acad. Sci. USA 106, 12483\u201312488 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR221","doi-asserted-by":"crossref","first-page":"13877","DOI":"10.1073\/pnas.97.25.13877","volume":"97","author":"TB Freeman","year":"2000","unstructured":"Freeman, T. B. et al. Transplanted fetal striatum in Huntington\u2019s disease: phenotypic development and lack of pathology. Proc. Natl Acad. Sci. USA 97, 13877\u201313882 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR222","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/bs.pbr.2016.12.011","volume":"230","author":"AC Bachoud-Levi","year":"2017","unstructured":"Bachoud-Levi, A. C. From open to large-scale randomized cell transplantation trials in Huntington\u2019s disease: lessons from the multicentric intracerebral grafting in Huntington\u2019s disease trial (MIG-HD) and previous pilot studies. Prog. Brain Res. 230, 227\u2013261 (2017).","journal-title":"Prog. Brain Res."},{"key":"389_CR223","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild, E. J. & Tabrizi, S. J. Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol. 16, 837\u2013847 (2017).","journal-title":"Lancet Neurol."},{"key":"389_CR224","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.neuron.2019.05.001","volume":"102","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J., Ghosh, R. & Leavitt, B. R. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 102, 899 (2019).","journal-title":"Neuron"},{"key":"389_CR225","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","volume":"78","author":"JM Lee","year":"2012","unstructured":"Lee, J. M. et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78, 690\u2013695 (2012).","journal-title":"Neurology"},{"key":"389_CR226","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74, 1031\u20131044 (2012).","journal-title":"Neuron"},{"key":"389_CR227","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.neuron.2012.06.001","volume":"74","author":"X-H Lu","year":"2012","unstructured":"Lu, X.-H. & Yang, X. W. \u201cHuntingtin holiday\u201d: progress toward an antisense therapy for Huntington\u2019s disease. Neuron 74, 964\u2013966 (2012).","journal-title":"Neuron"},{"key":"389_CR228","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-130057","volume":"2","author":"LM Stanek","year":"2013","unstructured":"Stanek, L. M. et al. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington\u2019s disease. J. Huntington\u2019s Dis. 2, 217\u2013228 (2013).","journal-title":"J. Huntington\u2019s Dis."},{"key":"389_CR229","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","volume":"24","author":"J Miniarikova","year":"2017","unstructured":"Miniarikova, J. et al. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease. Gene Ther. 24, 630\u2013639 (2017).","journal-title":"Gene Ther."},{"key":"389_CR230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier, L. R. et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127\u2013138 (2004).","journal-title":"Cell"},{"key":"389_CR231","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","volume":"269","author":"MP Duyao","year":"1995","unstructured":"Duyao, M. P. et al. Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh. Science 269, 407\u2013410 (1995).","journal-title":"Science"},{"key":"389_CR232","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","volume":"26","author":"I Dragatsis","year":"2000","unstructured":"Dragatsis, I., Levine, M. S. & Zeitlin, S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26, 300\u2013306 (2000).","journal-title":"Nat. Genet."},{"key":"389_CR233","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/emboj.2008.133","volume":"27","author":"E Colin","year":"2008","unstructured":"Colin, E. et al. Huntingtin phosphorylation acts as a molecular switch for anterograde\/retrograde transport in neurons. EMBO J. 27, 2124\u20132134 (2008).","journal-title":"EMBO J."},{"key":"389_CR234","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/hmg\/ddl467","volume":"16","author":"AN Strehlow","year":"2007","unstructured":"Strehlow, A. N., Li, J. Z. & Myers, R. M. Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space. Hum. Mol. Genet. 16, 391\u2013409 (2007).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/exnr.1998.6832","volume":"152","author":"J Velier","year":"1998","unstructured":"Velier, J. et al. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 152, 34\u201340 (1998).","journal-title":"Exp. Neurol."},{"key":"389_CR236","first-page":"1335","volume":"7","author":"H Brandstaetter","year":"2014","unstructured":"Brandstaetter, H., Kruppa, A. J. & Buss, F. Huntingtin is required for ER-to-Golgi transport and for secretory vesicle fusion at the plasma membrane. Dis. Model. Mech. 7, 1335\u20131340 (2014).","journal-title":"Dis. Model. Mech."},{"key":"389_CR237","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tcb.2009.01.005","volume":"19","author":"JP Caviston","year":"2009","unstructured":"Caviston, J. P. & Holzbaur, E. L. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 19, 147\u2013155 (2009).","journal-title":"Trends Cell Biol."},{"key":"389_CR238","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1074\/jbc.M103946200","volume":"277","author":"KB Kegel","year":"2002","unstructured":"Kegel, K. B. et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277, 7466\u20137476 (2002).","journal-title":"J. Biol. Chem."},{"key":"389_CR239","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"C Zuccato","year":"2003","unstructured":"Zuccato, C. et al. Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76\u201383 (2003).","journal-title":"Nat. Genet."},{"key":"389_CR240","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/hmg\/ddt499","volume":"23","author":"KN McFarland","year":"2014","unstructured":"McFarland, K. N. et al. MeCP2: a novel huntingtin interactor. Hum. Mol. Genet. 23, 1036\u20131044 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR241","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0896-6273(95)90346-1","volume":"14","author":"M DiFiglia","year":"1995","unstructured":"DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14, 1075\u20131081 (1995).","journal-title":"Neuron"},{"key":"389_CR242","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1093\/hmg\/ddq358","volume":"19","author":"E Marcora","year":"2010","unstructured":"Marcora, E. & Kennedy, M. B. The Huntington\u2019s disease mutation impairs huntingtin\u2019s role in the transport of NF-\u03baB from the synapse to the nucleus. Hum. Mol. Genet. 19, 4373\u20134384 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR243","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.1523\/JNEUROSCI.4699-13.2014","volume":"34","author":"SU McKinstry","year":"2014","unstructured":"McKinstry, S. U. et al. Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits. J. Neurosci. 34, 9455\u20139472 (2014).","journal-title":"J. Neurosci."},{"key":"389_CR244","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/jcs.115.5.941","volume":"115","author":"G Hoffner","year":"2002","unstructured":"Hoffner, G., Kahlem, P. & Djian, P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington\u2019s disease. J. Cell Sci. 115, 941\u2013948 (2002).","journal-title":"J. Cell Sci."},{"key":"389_CR245","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1073\/pnas.0610628104","volume":"104","author":"JP Caviston","year":"2007","unstructured":"Caviston, J. P., Ross, J. L., Antony, S. M., Tokito, M. & Holzbaur, E. L. Huntingtin facilitates dynein\/dynactin-mediated vesicle transport. Proc. Natl Acad. Sci. USA 104, 10045\u201310050 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR246","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.1523\/JNEUROSCI.1831-07.2007","volume":"27","author":"SL Anne","year":"2007","unstructured":"Anne, S. L., Saudou, F. & Humbert, S. Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J. Neurosci. 27, 7318\u20137328 (2007).","journal-title":"J. Neurosci."},{"key":"389_CR247","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820\u20135825 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR248","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","volume":"16","author":"NR Franich","year":"2008","unstructured":"Franich, N. R. et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease. Mol. Ther. 16, 947\u2013956 (2008).","journal-title":"Mol. Ther."},{"key":"389_CR249","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol. Ther. 19, 2152\u20132162 (2011).","journal-title":"Mol. Ther."},{"key":"389_CR250","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin, R. et al. Six-month partial suppression of huntingtin is well tolerated in the adult rhesus striatum. Brain 135, 1197\u20131209 (2012).","journal-title":"Brain"},{"key":"389_CR251","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1073\/pnas.1524575113","volume":"113","author":"G Wang","year":"2016","unstructured":"Wang, G., Liu, X., Gaertig, M. A., Li, S. & Li, X. J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc. Natl Acad. Sci. USA 113, 3359\u20133364 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR252","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02257483","volume":"20","author":"CM Ambrose","year":"1994","unstructured":"Ambrose, C. M. et al. Structure and expression of the Huntington\u2019s disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat. Cell Mol. Genet. 20, 27\u201338 (1994).","journal-title":"Somat. Cell Mol. Genet."},{"key":"389_CR253","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","volume":"49","author":"KT Gagnon","year":"2010","unstructured":"Gagnon, K. T. et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49, 10166\u201310178 (2010).","journal-title":"Biochemistry"},{"key":"389_CR254","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","volume":"150","author":"D Yu","year":"2012","unstructured":"Yu, D. et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150, 895\u2013908 (2012).","journal-title":"Cell"},{"key":"389_CR255","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","volume":"109","author":"M Garriga-Canut","year":"2012","unstructured":"Garriga-Canut, M. et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice. Proc. Natl Acad. Sci. USA 109, E3136\u2013E3145 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR256","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","volume":"19","author":"PH van Bilsen","year":"2008","unstructured":"van Bilsen, P. H. et al. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington\u2019s disease patient-derived fibroblasts. Hum. Gene Ther. 19, 710\u2013719 (2008).","journal-title":"Hum. Gene Ther."},{"key":"389_CR257","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys, A. M., Ebanks, S. A., Keiser, M. S. & Davidson, B. L. CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol. Ther. 25, 12\u201323 (2017).","journal-title":"Mol. Ther."},{"key":"389_CR258","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin, J. W. et al. Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum. Mol. Genet. 25, 4566\u20134576 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"389_CR259","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nbt.2376","volume":"30","author":"M Lindow","year":"2012","unstructured":"Lindow, M. et al. Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat. Biotechnol. 30, 920\u2013923 (2012).","journal-title":"Nat. Biotechnol."},{"key":"389_CR260","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/mt.2015.128","volume":"23","author":"C Kay","year":"2015","unstructured":"Kay, C. et al. Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry. Mol. Ther. 23, 1759\u20131771 (2015).","journal-title":"Mol. Ther."},{"key":"389_CR261","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","volume":"217","author":"MS Lombardi","year":"2009","unstructured":"Lombardi, M. S. et al. A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 217, 312\u2013319 (2009).","journal-title":"Exp. Neurol."},{"key":"389_CR262","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister, E. L. et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr. Biol. 19, 774\u2013778 (2009).","journal-title":"Curr. Biol."},{"key":"389_CR263","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten, R. L., Rossi, J. J. & Han, S. P. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug. Discov. 18, 421\u2013446 (2019).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"389_CR264","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509\u2013524 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"389_CR265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12551-017-0392-1","volume":"10","author":"T Ahmadzada","year":"2018","unstructured":"Ahmadzada, T., Reid, G. & McKenzie, D. R. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys. Rev. 10, 69\u201386 (2018).","journal-title":"Biophys. Rev."},{"key":"389_CR266","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","volume":"12","author":"E Rodriguez-Lebron","year":"2005","unstructured":"Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S. & Mandel, R. J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice. Mol. Ther. 12, 618\u2013633 (2005).","journal-title":"Mol. Ther."},{"key":"389_CR267","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","volume":"53","author":"YL Wang","year":"2005","unstructured":"Wang, Y. L. et al. Clinico-pathological rescue of a model mouse of Huntington\u2019s disease by siRNA. Neurosci. Res. 53, 241\u2013249 (2005).","journal-title":"Neurosci. Res."},{"key":"389_CR268","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","volume":"104","author":"M DiFiglia","year":"2007","unstructured":"DiFiglia, M. et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl Acad. Sci. USA 104, 17204\u201317209 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR269","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","volume":"343","author":"Y Machida","year":"2006","unstructured":"Machida, Y. et al. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Commun. 343, 190\u2013197 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"389_CR270","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau, R. L. et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice. Mol. Ther. 17, 1053\u20131063 (2009).","journal-title":"Mol. Ther."},{"key":"389_CR271","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","volume":"105","author":"JL McBride","year":"2008","unstructured":"McBride, J. L. et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl Acad. Sci. USA 105, 5868\u20135873 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR272","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","volume":"65","author":"V Drouet","year":"2009","unstructured":"Drouet, V. et al. Sustained effects of nonallele-specific huntingtin silencing. Ann. Neurol. 65, 276\u2013285 (2009).","journal-title":"Ann. Neurol."},{"key":"389_CR273","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"LM Stanek","year":"2014","unstructured":"Stanek, L. M. et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum. Gene Ther. 25, 461\u2013474 (2014).","journal-title":"Hum. Gene Ther."},{"key":"389_CR274","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hum.2008.928","volume":"19","author":"AR de Fougerolles","year":"2008","unstructured":"de Fougerolles, A. R. Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther. 19, 125\u2013132 (2008).","journal-title":"Hum. Gene Ther."},{"key":"389_CR275","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358\u2013378 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"389_CR276","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s11689-018-9234-0","volume":"10","author":"EA Lykken","year":"2018","unstructured":"Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A. & Gray, S. J. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J. Neurodev. Disord. 10, 16 (2018).","journal-title":"J. Neurodev. Disord."},{"key":"389_CR277","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/mt.2013.289","volume":"22","author":"BD Dufour","year":"2014","unstructured":"Dufour, B. D., Smith, C. A., Clark, R. L., Walker, T. R. & McBride, J. L. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington\u2019s disease mice. Mol. Ther. 22, 797\u2013810 (2014).","journal-title":"Mol. Ther."},{"key":"389_CR278","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204\u2013209 (2016).","journal-title":"Nat. Biotechnol."},{"key":"389_CR279","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","volume":"665","author":"Y Matsuzaki","year":"2018","unstructured":"Matsuzaki, Y. et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci. Lett. 665, 182\u2013188 (2018).","journal-title":"Neurosci. Lett."},{"key":"389_CR280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","volume":"9","author":"AL Jackson","year":"2010","unstructured":"Jackson, A. L. & Linsley, P. S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug. Discov. 9, 57\u201367 (2010).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"389_CR281","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","volume":"441","author":"D Grimm","year":"2006","unstructured":"Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways. Nature 441, 537\u2013541 (2006).","journal-title":"Nature"},{"key":"389_CR282","first-page":"434","volume":"7","author":"F Borel","year":"2011","unstructured":"Borel, F. et al. In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. J. RNAi Gene Silencing 7, 434\u2013442 (2011).","journal-title":"J. RNAi Gene Silencing"},{"key":"389_CR283","first-page":"331","volume":"8","author":"Z Meng","year":"2017","unstructured":"Meng, Z. & Lu, M. RNA interference-induced innate immunity, off-target effect, or immune adjuvant? Front. Immunol. 8, 331 (2017).","journal-title":"Front. Immunol."},{"key":"389_CR284","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"V Louis Jeune","year":"2013","unstructured":"Louis Jeune, V., Joergensen, J. A., Hajjar, R. J. & Weber, T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59\u201367 (2013).","journal-title":"Hum. Gene Ther. Methods"},{"key":"389_CR285","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","volume":"75","author":"MS Rafii","year":"2018","unstructured":"Rafii, M. S. et al. Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol. 75, 834\u2013841 (2018).","journal-title":"JAMA Neurol."},{"key":"389_CR286","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","volume":"9","author":"AV Kristen","year":"2019","unstructured":"Kristen, A. V. et al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener. Dis. Manag. 9, 5\u201323 (2019).","journal-title":"Neurodegener. Dis. Manag."},{"key":"389_CR287","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"389_CR288","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/2211738506666180611100416","volume":"6","author":"R Shankar","year":"2018","unstructured":"Shankar, R., Joshi, M. & Pathak, K. Lipid nanoparticles: a novel approach for brain targeting. Pharm. Nanotechnol. 6, 81\u201393 (2018).","journal-title":"Pharm. Nanotechnol."},{"key":"389_CR289","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467\u20131475 (2017).","journal-title":"Mol. Ther."},{"key":"389_CR290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12951-016-0177-x","volume":"14","author":"AR Neves","year":"2016","unstructured":"Neves, A. R., Queiroz, J. F. & Reis, S. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J. Nanobiotechnol. 14, 27 (2016).","journal-title":"J. Nanobiotechnol."},{"key":"389_CR291","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156452","volume":"11","author":"M Salvalaio","year":"2016","unstructured":"Salvalaio, M. et al. Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS ONE 11, e0156452 (2016).","journal-title":"PLoS ONE"},{"key":"389_CR292","unstructured":"uniQure. uniQure announces FDA clearance of investigational new drug application for AMT-130 in Huntington\u2019s disease. https:\/\/www.globenewswire.com\/news-release\/2019\/01\/22\/1703263\/0\/en\/uniQure-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AMT-130-in-Huntington-s-Disease.html (2019)."},{"key":"389_CR293","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","volume":"26","author":"MM Evers","year":"2018","unstructured":"Evers, M. M. et al. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease minipig model. Mol. Ther. 26, 2163\u20132177 (2018).","journal-title":"Mol. Ther."},{"key":"389_CR294","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/mtm.2016.37","volume":"3","author":"P Hadaczek","year":"2016","unstructured":"Hadaczek, P. et al. Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington\u2019s disease. Mol. Ther. Methods Clin. Dev. 3, 16037 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"389_CR295","unstructured":"Voyager Therapeutics. Voyager Therapeutics announces preclinical data for Huntington\u2019s disease and amyotrophic lateral sclerosis programs at the Congress of the European Society of Gene and Cell Therapy. https:\/\/www.globenewswire.com\/news-release\/2018\/10\/16\/1621781\/0\/en\/Voyager-Therapeutics-Announces-Preclinical-Data-for-Huntington-s-Disease-and-Amyotrophic-Lateral-Sclerosis-Programs-at-the-Congress-of-the-European-Society-of-Gene-and-Cell-Therapy.html (2018)."},{"key":"389_CR296","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett, C. F. & Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259\u2013293 (2010).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"389_CR297","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9\u201321 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"389_CR298","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett, C. F. Therapeutic antisense oligonucleotides are coming of age. Annu. Rev. Med. 70, 307\u2013321 (2019).","journal-title":"Annu. Rev. Med."},{"key":"389_CR299","volume":"1","author":"DA Wolf","year":"2016","unstructured":"Wolf, D. A. et al. Dynamic dual-isotope molecular imaging elucidates principles for optimizing intrathecal drug delivery. JCI Insight 1, e85311 (2016).","journal-title":"JCI Insight"},{"key":"389_CR300","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"},{"key":"389_CR301","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm.3514","volume":"20","author":"N Wang","year":"2014","unstructured":"Wang, N. et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington\u2019s disease. Nat. Med. 20, 536\u2013541 (2014).","journal-title":"Nat. Med."},{"key":"389_CR302","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond, S. M. et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl Acad. Sci. USA 113, 10962\u201310967 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"389_CR303","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","volume":"59","author":"HS Min","year":"2020","unstructured":"Min, H. S. et al. Systemic brain delivery of antisense oligonucleotides across the blood-brain barrier with a glucose-coated polymeric nanocarrier. Angew. Chem. Int. Ed. Engl. 59, 8173\u20138180 (2020).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"389_CR304","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"389_CR305","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller, T. M. et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435\u2013442 (2013).","journal-title":"Lancet Neurol."},{"key":"389_CR306","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02623699 (2020)."},{"key":"389_CR307","doi-asserted-by":"crossref","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","volume":"10","author":"AL Southwell","year":"2018","unstructured":"Southwell, A. L. et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease. Sci. Transl Med. 10, eaar3959 (2018).","journal-title":"Sci. Transl Med."},{"key":"389_CR308","unstructured":"Ducray, P. S. et al. AAN Presentation 2019: Translational pharmacokinetic\/pharmacodynamic (PK\/PD) modeling strategy to support RG6042 dose selection in Huntington\u2019s disease (HD). https:\/\/medically.roche.com\/en\/search\/pdfviewer.2e65a24a-ffc3-4736-9154-17d3383c8a60.html?cid=slprxx1905nehdaan2019 (2019)."},{"issue":"15 Suppl.","key":"389_CR309","doi-asserted-by":"crossref","first-page":"S16.005","DOI":"10.1212\/WNL.92.15_supplement.S16.005","volume":"92","author":"PS Ducray","year":"2019","unstructured":"Ducray, P. S. et al. Translational pharmacokinetic\/pharmacodynamic (PK\/PD) modeling strategy to support RG6042 dose selection in Huntington\u2019s disease (HD) [abstract]. Neurology 92 (Suppl. 15), S16.005 (2019).","journal-title":"Neurology"},{"key":"389_CR310","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","volume":"89","author":"SA Schobel","year":"2017","unstructured":"Schobel, S. A. et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology 89, 2495\u20132502 (2017).","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"389_CR311","first-page":"A48","volume":"89","author":"D Trundell","year":"2018","unstructured":"Trundell, D. et al. F23 Validity, reliability, ability to detect change and meaningful within-patient change of the CUHDRS [abstract]. J. Neurol. Neurosurg. Psychiatry 89 (Suppl. 1), A48 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"16 Suppl.","key":"389_CR312","doi-asserted-by":"crossref","first-page":"P2.006","DOI":"10.1212\/WNL.88.16_supplement.P2.006","volume":"88","author":"S Hersch","year":"2017","unstructured":"Hersch, S. et al. Multicenter, randomized, double-blind, placebo-controlled phase 1b\/2a studies of WVE-120101 and WVE-120102 in patients with Huntington\u2019s disease [abstract]. Neurology 88 (Suppl. 16), P2.006 (2017).","journal-title":"Neurology"},{"key":"389_CR313","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171127","volume":"12","author":"NA Datson","year":"2017","unstructured":"Datson, N. A. et al. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS ONE 12, e0171127 (2017).","journal-title":"PLoS ONE"},{"key":"389_CR314","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","volume":"90","author":"J Jiang","year":"2016","unstructured":"Jiang, J. et al. Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90, 535\u2013550 (2016).","journal-title":"Neuron"},{"key":"389_CR315","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nn.4014","volume":"18","author":"K Becanovic","year":"2015","unstructured":"Becanovic, K. et al. A SNP in the HTT promoter alters NF-\u03baB binding and is a bidirectional genetic modifier of Huntington disease. Nat. Neurosci. 18, 807\u2013816 (2015).","journal-title":"Nat. Neurosci."},{"key":"389_CR316","unstructured":"Bhattacharyya, A. Identification and development of orally administered, CNS-penetrant small molecules that lower huntingtin protein levels by inducing a novel splicing event that alters the stability of huntingtin mRNA. https:\/\/chdifoundation.org\/2019-conference\/#bhattacharyya (2019)."},{"key":"389_CR317","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin, N. A. et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345, 688\u2013693 (2014).","journal-title":"Science"},{"key":"389_CR318","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02240355 (2016)."},{"key":"389_CR319","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02633709 (2018)."},{"key":"389_CR320","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03032172 (2020)."},{"key":"389_CR321","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02908685 (2020)."},{"key":"389_CR322","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02913482 (2020)."},{"key":"389_CR323","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.cell.2011.12.032","volume":"148","author":"CR Liu","year":"2012","unstructured":"Liu, C. R. et al. Spt4 is selectively required for transcription of extended trinucleotide repeats. Cell 148, 690\u2013701 (2012).","journal-title":"Cell"},{"key":"389_CR324","volume":"11","author":"HM Cheng","year":"2015","unstructured":"Cheng, H. M. et al. Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdown. PLoS Genet. 11, e1005043 (2015).","journal-title":"PLoS Genet."},{"key":"389_CR325","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-biochem-010909-095056","volume":"79","author":"A Klug","year":"2010","unstructured":"Klug, A. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu. Rev. Biochem. 79, 213\u2013231 (2010).","journal-title":"Annu. Rev. Biochem."},{"key":"389_CR326","doi-asserted-by":"crossref","first-page":"19","DOI":"10.32607\/20758251-2014-6-3-19-40","volume":"6","author":"AA Nemudryi","year":"2014","unstructured":"Nemudryi, A. A., Valetdinova, K. R., Medvedev, S. P. & Zakian, S. M. TALEN and CRISPR\/Cas genome editing systems: tools of discovery. Acta Naturae 6, 19\u201340 (2014).","journal-title":"Acta Naturae"},{"key":"389_CR327","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04252-2","volume":"9","author":"M Adli","year":"2018","unstructured":"Adli, M. The CRISPR tool kit for genome editing and beyond. Nat. Commun. 9, 1911 (2018).","journal-title":"Nat. Commun."},{"key":"389_CR328","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JHD-160222","volume":"6","author":"TB Malankhanova","year":"2017","unstructured":"Malankhanova, T. B., Malakhova, A. A., Medvedev, S. P. & Zakian, S. M. Modern genome editing technologies in Huntington\u2019s disease research. J. Huntington\u2019s Dis. 6, 19\u201331 (2017).","journal-title":"J. Huntington\u2019s Dis."},{"key":"389_CR329","volume":"9","author":"GF Richard","year":"2014","unstructured":"Richard, G. F. et al. Highly specific contractions of a single CAG\/CTG trinucleotide repeat by TALEN in yeast. PLoS ONE 9, e95611 (2014).","journal-title":"PLoS ONE"},{"key":"389_CR330","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3727\/096368916X690863","volume":"25","author":"KD Fink","year":"2016","unstructured":"Fink, K. D. et al. Allele-specific reduction of the mutant huntingtin allele using transcription activator-like effectors in human Huntington\u2019s disease fibroblasts. Cell Transplant. 25, 677\u2013686 (2016).","journal-title":"Cell Transplant."},{"key":"389_CR331","volume":"6","author":"SM Heman-Ackah","year":"2016","unstructured":"Heman-Ackah, S. M., Bassett, A. R. & Wood, M. J. Precision modulation of neurodegenerative disease-related gene expression in human iPSC-derived neurons. Sci. Rep. 6, 28420 (2016).","journal-title":"Sci. Rep."},{"key":"389_CR332","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnins.2018.00075","volume":"12","author":"M Dabrowska","year":"2018","unstructured":"Dabrowska, M., Juzwa, W., Krzyzosiak, W. J. & Olejniczak, M. Precise excision of the CAG tract from the huntingtin gene by Cas9 nickases. Front. Neurosci. 12, 75 (2018).","journal-title":"Front. Neurosci."},{"key":"389_CR333","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/d41586-019-01906-z","volume":"570","author":"H Ledford","year":"2019","unstructured":"Ledford, H. CRISPR babies: when will the world be ready? Nature 570, 293\u2013296 (2019).","journal-title":"Nature"},{"key":"389_CR334","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","volume":"4","author":"XH Zhang","year":"2015","unstructured":"Zhang, X. H., Tee, L. Y., Wang, X. G., Huang, Q. S. & Yang, S. H. Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol. Ther. Nucleic Acids 4, e264 (2015).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"389_CR335","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone, M. C. & O\u2019Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529\u20131541 (2018).","journal-title":"Leukemia"},{"key":"389_CR336","doi-asserted-by":"crossref","unstructured":"Trundell, D. et al. Defining clinically meaningful change on the composite Unified Huntington\u2019s Disease Rating Scale (cUHDRS) (P1.8-043). Neurology 92 (Suppl. P1.8-043) (2019).","DOI":"10.1212\/WNL.92.15_supplement.P1.8-043"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-0389-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-0389-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-0389-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T20:39:59Z","timestamp":1723408799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-0389-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":336,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1038\/s41582-020-0389-4","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"29 June 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the past two years S.J.T. has undertaken consultancy services, including advisory boards, with F. Hoffmann-La Roche Ltd, Ixitech Technologies, Takeda Pharmaceuticals International and Triplet therapeutics. All honoraria for these consultancies were paid to University College London, S.J.T.\u2019s employer. Through the offices of UCL Consultants Ltd, a wholly owned subsidiary of University College London, S.J.T. has undertaken consultancy services for Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, GSK, Heptares Therapeutics, LoQus therapeutics, Takeda Pharmaceuticals Ltd, TEVA Pharmaceuticals, Triplet therapeutics, UCB Pharma S.A., University College Irvine and Vertex Pharmaceuticals Incorporated. S.J.T. receives grant funding for her research from Takeda Pharmaceuticals and Cantervale Limited. C.A.R. is chair of the Research Advisory Board of the Huntington Study Group. Within the past two years, C.A.R. has consulted for Annexon, Roche, Sage and uniQure. C.A.R. receives funding\u00a0for Huntington disease research from F. Hoffman-La Roche. Through UCL Consultants Ltd, a wholly owned subsidiary of University College London. E.J.W. has served on scientific advisory boards for F. Hoffmann\u2013La Roche, Ionis, Mitoconix, Novartis, PTC Therapeutics, Shire, Takeda Pharmaceuticals and Wave Life Sciences. M.D.F. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}